Citadel Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Citadel Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,800	Closed	-$15K	–	15316
2021 Q4	$15K	Buy	12,800 +2,300	+22%	+$3.43K	﹤0.01%	13633
2021 Q3	$20K	Sell	10,500 -13,600	-56%	-$26.7K	﹤0.01%	13643
2021 Q2	$56K	Buy	24,100 +8,200	+52%	+$19.8K	﹤0.01%	13291
2021 Q1	$43K	Buy	15,900 +1,200	+8%	+$3.55K	﹤0.01%	12963
2020 Q4	$36K	Sell	14,700 -6,000	-29%	-$13.7K	﹤0.01%	10681
2020 Q3	$47K	Buy	20,700 +8,500	+70%	+$22.3K	﹤0.01%	9629
2020 Q2	$28K	Sell	12,200 -900	-7%	-$2.07K	﹤0.01%	9482
2020 Q1	$23K	Buy	+13,100	New	+$26.5K	﹤0.01%	9272
2017 Q3	–	Sell	-1,288	Closed	-$54K	–	8359
2017 Q2	$54K	Buy	+1,288	New	+$62K	﹤0.01%	7077

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Citadel Advisors's GNCA Position: Q2 2022 in Review

Citadel Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 1,843,112 shares — an estimated $2.3M sold.

Citadel Advisors first reported a position in GNCA in Q2 2017 and held it in 15 quarters. The position peaked at $4.96M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Citadel Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 1,843,112 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $2.3M.
Citadel Advisors first reported a position in Genocea Biosciences, Inc. in Q2 2017 and held it in 15 quarters.
Citadel Advisors's Genocea Biosciences, Inc. position peaked at $4.96M in Q1 2021.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.